focus -WSS

focus

author：comprehensive 2025-10-01 15:28:22 - browse：95

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Ohioans vote in high

leisure time

WSS

How a scoliosis diagnosis changed the life of one young dancer

Sage's campaign to raise awareness of postpartum depression hits a nerve

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Federal weight loss drug coverage is 30 years out of date

focus

focus

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Feng Zhang, Grail founder join forces on new gene editing startup

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

An Ebola outbreak presents a new mystery involving children

Cancer drug shortages should be causing more outrage

J&J to buy cancer drug developer Ambrx Biopharma

United colonoscopy coverage change 'may cost lives,' doctors say

Astronauts get first look at the spacecraft that will fly them around the moon

As demand for Covid shots wanes, Moderna seeks its next success

J&J to buy cancer drug developer Ambrx Biopharma

explore

Judge rejects Trump's counterclaim against E. Jean Carroll

3 medical device trends to watch in 2024

New weight loss drugs work. But how can they best be used?

Discs beat pads, tampons for heavy menstrual flow, new study shows

Morgan Health, with ambitious aims, wants you to know it’s still here

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

knowledge

focus

leisure time

knowledge